UPDATE: Morgan Keegan Raises PT to $62 on Ventas

A report from Morgan Keegan reiterates its Outperform rating and raises its price target from $60 to $62 and on Ventas (NYSE: VTR).

The report states, “Ventas generated strong results from its first full quarter to reflect the $3.1 billion Atria Senior Living and $7.4 billion Nationwide Health Properties acquisitions. Samestore cash NOI grew 3.4% (excluding a one-time payment received last year), resulting in FFO of $0.88 per share compared to our $0.80 estimate."

VTR closed Friday at $54.30.